Pompe Disease Therapy Receives Orphan Designation

Novazyme Pharmaceuticals, Inc. has received formal notification from the Office of Orphan Products Development at the FDA that its proprietary, highly phosphorylated enzyme replacement therapy for the treatment of Pompe Disease has been granted orphan drug status. This notification from the FDA represents the first official validation of Novazyme‘s core phosphorylation technology platform with which Read more about Pompe Disease Therapy Receives Orphan Designation[…]

eli lilly

Lilly And Ceptyr Announce Drug Discovery Collaboration

Eli Lilly and Company and Ceptyr, Inc., have announced a two-year research collaboration for the discovery of small molecules to treat diabetes, obesity, and impaired glucose tolerance. The collaboration will focus on the phosphatase target, PTP1B, using Ceptyr’s proprietary assays and screening technology. Ceptyr will receive an upfront signing fee, research funding, milestone payments and Read more about Lilly And Ceptyr Announce Drug Discovery Collaboration[…]

bristol myers squibb

Squibb Receives Approval For Glucovance

Bristol-Myers Squibb Company has announced U.S. FDA has approved Glucovance (Glyburide and Metformin HCl Tablets) for use, along with diet and exercise, as initial drug therapy for people with type 2 diabetes. The drug was also approved as second-line therapy for patients with type 2 diabetes who are currently taking either or a sulfonylurea and Read more about Squibb Receives Approval For Glucovance[…]

Curagen And Gemini Enter Genome Wide Drug Target Discovery And Pharmacogenetics Collaboration

CuraGen Corporation, an integrated genomics based drug discovery and development company, and Gemini Genomics plc, announced today the largest collaboration to date linking cSNPs (human genetic variations) and clinical information to identify and validate novel drug targets for use in the discovery and development of pharmaceutical and diagnostic products. Specifically, CuraGen and Gemini scientists will Read more about Curagen And Gemini Enter Genome Wide Drug Target Discovery And Pharmacogenetics Collaboration[…]

generex biotechnology corporation

Generex Receives License From Presspart

Generex Biotechnology Corporation and Presspart Group Limited have entered into a commercial supply agreement for a key component of Generex’s RapidMist device. Under the agreement, Generex will purchase its requirements of pharmaceutical aerosol cans used for the buccal delivery of insulin from UK-based Presspart. Presspart has granted an exclusive license to Generex for the use Read more about Generex Receives License From Presspart[…]

Ligand Pharmaceuticals

Ligand, Lilly Agree Second Extension To R&D Collaboration

Ligand Pharmaceuticals and Eli Lilly and Company will extend until November 2004 their research collaboration focused on discovering novel drugs for type II diabetes and cardiovascular disorders. This represents the second extension of the collaboration with Lilly, and further strengthens both partners’ confidence in continued success going forward. The Lilly-Ligand collaboration, which began in 1997, Read more about Ligand, Lilly Agree Second Extension To R&D Collaboration[…]

Johnson &Johnson’s Epilepsy Drug Leads To Weight Loss

Johnson & Johnson have announced that obese patients lost over 11 percent of their body weight one year after being treated with the company’s anti-epilepsy drug Topamax.The firm is encouraged to continue developing the medicine as a weight-loss medicine.Topamax is currently approved only for treatment of epilepsy, but the New Brunswick, N.J.-based firm is also Read more about Johnson &Johnson’s Epilepsy Drug Leads To Weight Loss[…]

Ligand Pharmaceuticals

Ligand And Lilly Advance Novel Drugs

Ligand Pharmaceuticals Incorporated has announced that LY510929, a novel PPAR agonist, and a back-up compound have been declared clinical candidates for development as novel oral treatments for type 2 diabetes and cardiovascular disease. Ligand expects an Investigational New Drug Application (IND) to be filed with the FDA for LY510929 or the back-up compound in the Read more about Ligand And Lilly Advance Novel Drugs[…]